214 related articles for article (PubMed ID: 9100669)
21. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
Ferrer M; Schulze A; Gonzalez S; Ferreiro V; Ciavarelli P; Otero J; Giliberto F; Basso A; Szijan I
Neurosci Lett; 2010 Aug; 480(1):49-54. PubMed ID: 20553997
[TBL] [Abstract][Full Text] [Related]
23. NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH.
Szijan I; Rochefort D; Bruder C; Surace E; Machiavelli G; Dalamon V; Cotignola J; Ferreiro V; Campero A; Basso A; Dumanski JP; Rouleau GA
Neuromolecular Med; 2003; 3(1):41-52. PubMed ID: 12665675
[TBL] [Abstract][Full Text] [Related]
24. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas.
Singh PK; Gutmann DH; Fuller CE; Newsham IF; Perry A
Mod Pathol; 2002 May; 15(5):526-31. PubMed ID: 12011257
[TBL] [Abstract][Full Text] [Related]
25. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.
Goutebroze L; Brault E; Muchardt C; Camonis J; Thomas G
Mol Cell Biol; 2000 Mar; 20(5):1699-712. PubMed ID: 10669747
[TBL] [Abstract][Full Text] [Related]
26. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study.
Hitotsumatsu T; Iwaki T; Kitamoto T; Mizoguchi M; Suzuki SO; Hamada Y; Fukui M; Tateishi J
Acta Neuropathol; 1997 Mar; 93(3):225-32. PubMed ID: 9083553
[TBL] [Abstract][Full Text] [Related]
27. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
28. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
[TBL] [Abstract][Full Text] [Related]
29. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
30. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c).
Scoles DR; Yong WH; Qin Y; Wawrowsky K; Pulst SM
Hum Mol Genet; 2006 Apr; 15(7):1059-70. PubMed ID: 16497727
[TBL] [Abstract][Full Text] [Related]
31. [A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma].
Sanson M
Rev Neurol (Paris); 1996 Jan; 152(1):1-10. PubMed ID: 8729390
[TBL] [Abstract][Full Text] [Related]
32. Schwannomin isoform-1 interacts with syntenin via PDZ domains.
Jannatipour M; Dion P; Khan S; Jindal H; Fan X; Laganière J; Chishti AH; Rouleau GA
J Biol Chem; 2001 Aug; 276(35):33093-100. PubMed ID: 11432873
[TBL] [Abstract][Full Text] [Related]
33. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
[TBL] [Abstract][Full Text] [Related]
34. Neurofibromatosis type 2: a new mechanism of tumor suppression.
Lutchman M; Rouleau GA
Trends Neurosci; 1996 Sep; 19(9):373-7. PubMed ID: 8873351
[TBL] [Abstract][Full Text] [Related]
35. The mouse homologue of the neurofibromatosis type 2 gene is highly conserved.
Claudio JO; Marineau C; Rouleau GA
Hum Mol Genet; 1994 Jan; 3(1):185-90. PubMed ID: 8162023
[TBL] [Abstract][Full Text] [Related]
36. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatosis type 2.
Evans DG; Sainio M; Baser ME
J Med Genet; 2000 Dec; 37(12):897-904. PubMed ID: 11106352
[TBL] [Abstract][Full Text] [Related]
38. Role of Merlin/NF2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
40. Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.
Buccoliero AM; Gheri CF; Castiglione F; Ammannati F; Gallina P; Taddei A; Garbini F; Rossi Degl'Innocenti D; Arganini L; Di Lorenzo N; Mennonna P; Taddei GL
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):353-7. PubMed ID: 17721284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
